Last reviewed · How we verify
Rituximab-Dexamethasone-Lenalidomide
At a glance
| Generic name | Rituximab-Dexamethasone-Lenalidomide |
|---|---|
| Sponsor | Fondazione Italiana Linfomi - ETS |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (PHASE1, PHASE2)
- R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL (PHASE3)
- R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia (PHASE2)
- ZR2 Sequential Immunochemotherapy for Newly Treated MCL (PHASE2)
- Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas (PHASE2)
- A Phase II Study of the FIL on Elderly Frail Patients With DLBCL (PHASE2)
- DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma (PHASE2)
- Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: